Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diftalone SCHEMBL35351 | 1.00 | KMT2A (1.00) | KMT2ANPC1RAB9APKMALOX15 | |
| Diftalone SCHEMBL8196066 | 0.88 | KMT2A (0.78) | KMT2ANPC1RAB9APKMALOX15 | |
| Diftalone SCHEMBL28198200 | 0.87 | KMT2A (0.75) | KMT2ANPC1RAB9APKMALOX15 | |
| SCHEMBL11355286 | 0.82 | KMT2A (0.69) | KMT2ANPC1RAB9APKMALOX15 | |
| SCHEMBL23832541 | 0.81 | KMT2A (0.67) | KMT2ANPC1RAB9APKMALOX15 | |
| SCHEMBL29569183 | 0.81 | KMT2A (0.67) | KMT2ANPC1RAB9APKMALOX15 | |
| SCHEMBL31331343 | 0.81 | KMT2A (0.66) | KMT2ANPC1RAB9APKMALOX15 | |
| Hydrochloric Acid SCHEMBL4557636 | 0.80 | KMT2A (0.65) | KMT2ANPC1RAB9APKMALOX15 | |
| SCHEMBL14352086 | 0.80 | KMT2A (0.65) | KMT2ANPC1RAB9APKMALOX15 | |
| SCHEMBL2352069 | 0.80 | KMT2A (0.65) | KMT2ANPC1RAB9APKMALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335413-A2 | PROSTHETIC TISSUE VALVES | Cormatrix Cardiovascular, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| US-12616698-B2 | Methods for reducing liver fat and for treating fatty liver disorders | CORCEPT THERAPEUTICS INCORPORATED (US) | 2026-05-05 | — | — | US | disclosed |
| US-12262724-B2 | Poultry feed and drinking water composition comprising a stable, bioavailable silicon complex | SILINNOV SRCL (BE) | 2025-04-01 | — | — | US | disclosed |
| CN-118105478-A | Myostatin, activin, or activin receptor antagonists for use in treating obesity and related disorders | 诺华股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20240100052-A1 | METHODS FOR REDUCING LIVER FAT and FOR TREATING FATTY LIVER DISORDERS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-03-28 | — | — | US | disclosed |
| EP-4333848-A1 | METHODS FOR REDUCING LIVER FAT AND FOR TREATING FATTY LIVER DISORDERS | Corcept Therapeutics Incorporated (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240075030-A1 | Methods For Reducing Liver Fat and For Treating Fatty Liver Disorders | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-03-07 | — | — | US | disclosed |
| CN-110087684-B | Myostatin, activin, or activin receptor antagonists for use in treating obesity and related disorders | 诺华股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20220370446-A1 | Methods For Reducing Liver Fat and For Treating Fatty Liver Disorders | CORCEPT THERAPEUTICS INCORPORATED (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2022235647-A1 | METHODS FOR REDUCING LIVER FAT AND FOR TREATING FATTY LIVER DISORDERS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20220151263-A1 | POULTRY FEED AND DRINKING WATER COMPOSITION COMPRISING A STABLE, BIOAVAILABLE SILICON COMPLEX | SILINNOV SRCL (BE) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240075030-A1 | Methods For Reducing Liver Fat and For Treating Fatty Liver Disorders | FABP1, COLGALT1, LGALS3 | KMT2A 2726/4885NPC1 2303/4885RAB9A 4367/4885 |
| US-20240100052-A1 | METHODS FOR REDUCING LIVER FAT and FOR TREATING FATTY LIVER DISORDERS | FABP1, COLGALT1, LGALS3 | KMT2A 2726/4885NPC1 2303/4885RAB9A 4367/4885 |
| US-12616698-B2 | Methods for reducing liver fat and for treating fatty liver disorders | FABP1, LGALS3, COLGALT1 | KMT2A 2792/4885NPC1 1767/4885RAB9A 4442/4885 |
| US-20220370446-A1 | Methods For Reducing Liver Fat and For Treating Fatty Liver Disorders | FABP1, COLGALT1, LGALS3 | KMT2A 2726/4885NPC1 2303/4885RAB9A 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.